Page last updated: 2024-12-05

triphenylphosphine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triphenylphosphine, also known as PPh3, is a common organophosphorus compound with the formula P(C6H5)3. It is a white, crystalline solid that is soluble in organic solvents but insoluble in water. Triphenylphosphine is a versatile reagent in organic chemistry, and it is widely used in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and polymers. It serves as a ligand in coordination chemistry and a reagent in various reactions, including the Wittig reaction, the Staudinger reaction, and the Appel reaction. Triphenylphosphine is also used as a catalyst in a variety of reactions, such as the Heck reaction and the Suzuki reaction. It is a valuable reagent in the field of organic synthesis, catalysis, and coordination chemistry.'

triphenylphosphine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triphenylphosphine : A member of the class of tertiary phosphines that is phosphane in which the three hydrogens are replaced by phenyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11776
CHEMBL ID1448331
CHEBI ID183318
SCHEMBL ID101
SCHEMBL ID1679860
MeSH IDM0171516

Synonyms (109)

Synonym
AKOS009031542
pph3
triphenylphosphan
triphenylphosphin
phosphorus triphenyl
ph3p
CHEBI:183318 ,
triphenylphosphine 1m in thf
nsc215203
nsc-215203
inchi=1/c18h15p/c1-4-10-16(11-5-1)19(17-12-6-2-7-13-17)18-14-8-3-9-15-18/h1-15
triphenyl phosphine
NCGC00091416-01
trifenylfosfin [czech]
nsc 10
hsdb 4266
einecs 210-036-0
brn 0610776
triphenylphosphide
nsc 215203
ccris 4889
pp 360
triphenylphosphane
nsc10
triphenylphosphine
phosphine, triphenyl-
triphenylphosphorus
wln: rpr&r
nsc-10
603-35-0
triphenylphosphine, reagentplus(r), 99%
jandajel(tm)-triphenylphosphine, 50-100 mesh, extent of labeling: ~3.0 mmol/g p loading, 2 % cross-linked
triphenylphosphine, >=95.0% (gc)
T0519
A15679
NCGC00091416-03
triphenyl-phosphane
phosphorustriphenyl
dtxcid906251
dtxsid5026251 ,
tox21_303294
cas-603-35-0
NCGC00257211-01
tox21_202114
NCGC00259663-01
c18h15p
triphenyl phosphorous
FT-0689298
4-16-00-00951 (beilstein handbook reference)
ec 210-036-0
unii-26d26oa393
trifenylfosfin
26d26oa393 ,
BP-12577
FT-0632502
FT-0604360
triphenylphosphine [hsdb]
triphenylphosphine [inci]
triphenylphosphine [mi]
triphenylphosphorane
SCHEMBL101
triphenyl- phosphine
triphenylphophine
triphenyphospine
triphenyphosphine
tri-phenylphosphine
triphenyl phosphine resin
tri-phenylphospine
(c6h5)3p
tripbenylphosphine
triphenylphoshine
triphenyl phophine
triphenyiphosphine
triphenyiphoshine
tripheylphosphine
triphenyl phosphorus
triphenylphospine
triphenylphosphine-
p(ph)3
tripenylphosphine
triphenyl phosphin
triphenyl-phosphine
(ph)3p
triphenyl phospine
p(c6h5)3
SCHEMBL1679860
Q-201896
CHEMBL1448331
58079-51-9
FT-0698371
mfcd00003043
triphenylphosphine, powder
F1642-0085
triphenylphosphine, reagentplus(r), >=98.5%
triphenylphosphine, flakes
mfcd20489348
AT26025
triphenylphosphine, 98%
triphenylphospane
BCP01148
Q115493
AMY19190
triphenylphosphine;phosphine, triphenyl-;triphenylphosphane;triphenyl phosphine;triphenylphosphine phosphine, triphenyl- triphenylphosphane triphenyl phosphine
STL185621
fpz ,
EN300-19636
triphenylphosphine polystyrene (200-400 mesh, 0.8-1.5 mmol/g)
p 100 (accelerator)
triphenyl phosphide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The public interest steadily increases in the biological adverse effects caused by components released from resin-based dental restorations."( Cytotoxicity and induction of DNA double-strand breaks by components leached from dental composites in primary human gingival fibroblasts.
Carell, T; Durner, J; Eldenez, A; Geurtsen, W; Hickel, R; Kaina, B; Reichl, FX; Rothmund, L; Scherthan, H; Shehata, M; Styllou, P; Van Landuyt, K, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
reducing agentThe element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species.
NMR chemical shift reference compoundAny compound that produces a peak used to reference an NMR spectrum during data pre-processing.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
tertiary phosphineA compound derived from phosphane by substituting three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency50.11870.004023.8416100.0000AID485290
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency62.83843.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.33650.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency15.73880.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency49.49750.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency55.53710.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency42.06820.001022.650876.6163AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency62.31360.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency56.24670.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency60.09280.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency24.54120.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency30.05200.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency56.00480.000229.305416,493.5996AID743075
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency24.54120.023723.228263.5986AID743222
activating transcription factor 6Homo sapiens (human)Potency4.45190.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency2.753619.739145.978464.9432AID1159509
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency48.94800.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency3.21280.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency50.05390.000627.21521,122.0200AID651741; AID743202; AID743219
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1128675Cytotoxicity against mouse TA3/Ha cells after 48 hrs by neutral red assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice.
AID1128676Cytotoxicity against mouse multidrug-resistant TA3-MTX-R cells after 48 hrs by neutral red assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice.
AID1128677Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice.
AID1128678Cytotoxicity against mouse MM3MG cells after 48 hrs by neutral red assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (218)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.46)18.7374
1990's7 (3.21)18.2507
2000's75 (34.40)29.6817
2010's99 (45.41)24.3611
2020's36 (16.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.98 (24.57)
Research Supply Index5.41 (2.92)
Research Growth Index5.86 (4.65)
Search Engine Demand Index125.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other221 (99.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]